Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

Medicines Patent Pool, Novartis pen deal to boost access to ...

The Medicines Patent Pool (MPP) and Novartis have unveiled a new

Novartis eyes filings for leukaemia drug asciminib after pha...

A first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid leukaemia (CML) in a head-to-head trial, setting up reg

CVS rolls out digital messaging for meds adherence after pil...

Cancer Research UK gives $4m funding to Glasgow Uni CML proj...

Cancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to enable a pioneering study to help find new treatments for CML - chronic myeloid leuka

Pfizer leukaemia drug accepted by NICE

Bosulif is first drug to be funded following reassessment.